Aethlon Medical (OTC:AEMD) is looking to raise $2 million in an equity offering as it pursues a nod from the FDA for its Hemopurifier device.
The San Diego-based medical device company has so far raised $230,000 from 3 unnamed investors, according to a regulatory filing.
In June, Aethlon said the FDA granted an investigational device exemption for a feasibility study of its Hemopurifier device, designed to filter pathogens and cancer cells from human blood.
The 10-patient trial consists of patients with end-stage renal cancer who carry the hepatitis C virus. If successful, the trial will set Aethlon up for pivotal studies aimed at getting the device on the U.S. market for treating the blood disease.
In September, Aethlon named Dr. Douglas Taylor as chief scientific officer of its new subsidiary, Exosome Sciences, which was created to focus on exosome-based diagnostics.